N-myc has proapoptotic functions, yet it acts as an oncogene in neuroblastoma. Thus, antiapoptotic mechanisms have to be operative in neuroblastoma cells that antagonize the proapoptotic effects of N-myc. We conditionally activated N-myc in SH-EP neuroblastoma cells subjected to the trophic stress of serum or nutrient deprivation while changing the expression of Bcl-2, survivin and FLIP L , antiapoptotic molecules often overexpressed in poor prognosis neuroblastomas. Bcl-2 protected SH-EP cells from death during nutritional deprivation by activating energetically advantageous oxidative phosphorylation. N-myc overrode the metabolic protection provided by Bcl-2-induced oxidative phosphorylation by reestablishing the glycolytic phenotype and attenuated the antiapoptotic effect of Bcl-2 during metabolic stress. Survivin partially antagonized the growth suppressive function of N-myc in SH-EP neuroblastoma cells during serum deprivation whereas FLIP L did not. These findings advance our understanding of the functions of N-myc in neuroblastoma cells.
Introduction
Advanced and rapidly progressing neuroblastoma is often associated with amplification of the protooncogene MYCN (Seeger et al., 1985) , which reliably predicts poor prognosis (Brodeur et al., 1984; Look et al., 1991) . Most often MYCN copy number is proportional to expression of N-myc (Nisen et al., 1988; Wada et al., 1993) . Whether N-myc overexpression in the absence of MYCN amplification predicts poor outcome remains controversial (Nisen et al., 1988; Nakagawara et al., 1990; Slavc et al., 1990; Chan et al., 1997; Ichimiya et al., 1999; Cohn et al., 2000; Matthay, 2000; Tang et al., 2006) . The diverging effects of N-myc seen in patients with neuroblastoma are also reflected on the cellular level. N-myc stably overexpressed in single copy neuroblastoma cells leads to cytokine-independent proliferation in vitro and increased tumorigenicity in the mouse (Schweigerer et al., 1990) . These initial findings established the notion that overexpression of N-myc increases the tumor cells' malignancy. However, it has become apparent that N-myc also possesses a proapoptotic function. Exertion of the proapoptotic function of the myc family of proteins usually requires withdrawal of antiapoptotic survival factors such as serum deprivation (Ueda and Ganem, 1996; Jasty et al., 2001) or the application of a proapoptotic stimulus such as chemotherapy (Fulda et al., 1999) . Since N-myc has functions of a tumor suppressor when subjected to these stressors, mechanisms protecting against cell death must be in place to allow N-myc to maintain its oncogenic function (Hogarty, 2003; Goldsmith and Hogarty, 2005) . Protective mechanisms neuroblastoma cells use to attenuate the proapoptotic activity of N-myc are diverse and include upregulation of antiapoptotic or downregulation of proapoptotic intracellular proteins. The caspase-8 gene is hypermethylated in many neuroblastomas including those with amplification of MYCN (Hopkins-Donaldson et al., 2000; Teitz et al., 2000; Eggert et al., 2001) . Loss of caspase-8 expression has been shown to decrease N-myc-augmented apoptosis of neuroblastoma cells during serum deprivation (Teitz et al., 2000) . Caspase-8 is not only crucial in activating extrinsic death pathways, but is also important for efficient amplification of intrinsic apoptosis pathways, the latter being the predominant pathway triggered by N-myc. Thus, loss of caspase-8 may constitute a strong countermeasure to the proapoptotic effect of N-myc, while also affording protection against other apoptotic stressors such as those imposed by detachment and metastasis into distant microenvironments (Stupack et al., 2006) . However, recent evidence implies that loss of caspase-8 neither correlates with poor prognostic features of neuroblastoma nor with MYCN amplification (Fulda et al., 2006) , suggesting that loss of caspase-8 is not selected for to ablate N-mycaugmented apoptosis. Instead, as caspase-8 is silenced in neural cell precursors during development (Ricci-Vitiani et al., 2004) , lack of caspase-8 in neuroblastomas may reflect the developmental state of the tumor rather than a tumor-specific acquired alteration (Goldsmith and Hogarty, 2005) .
FLIP L is a structural homologue of caspase-8 lacking caspase activity. It is recruited to the death-inducing signaling complex (DISC) and, when overexpressed, acts as an inhibitor of apoptosis (IAP) (reviewed in (Krueger et al., 2001) ). Activation of the DISC by autocrine CD95L interacting with CD95 is thought to contribute to apoptosis induced by c-myc in rodent fibroblasts (Hueber et al., 1997; Juin et al., 1999) , suggesting that excess FLIP L activity might protect against c-mycinduced apoptosis. It has become evident that FLIP L at low, that is, physiological levels, may activate caspase-8 (Chang et al., 2002; Micheau et al., 2002; Boatright et al., 2004) , which can lead to apoptosis (Chang et al., 2002) . In contrast, FLIP L expressed at high levels exerts an antiapoptotic effect as demonstrated by a plethora of studies with various cancer cell lines, where the degree of FLIP L expression determined sensitivity or resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (Roth and Reed, 2004) . Conversely, knockdown of FLIP L sensitizes diverse tumor cell lines to TRAIL (Ganten et al., 2004; Sharp et al., 2005) . FLIP L is overexpressed in neuroblastoma, where it is believed to inhibit apoptosis (Poulaki et al., 2001) . However, the role of FLIP L in N-myc-augmented neuroblastoma cell death has not been examined yet.
Bcl-2 is a founding member of a family of pro-survival homologues that neutralize diverse death stressors to prevent mitochondria-mediated cell death. Furthermore, Bcl-2 cooperates to transform primary cells in concert with Myc proteins and accelerates MYC geneinduced oncogenesis (reviewed in (Nilsson and Cleveland, 2003) ). Bcl-2 may be overexpressed in patient neuroblastomas concomitant with MYCN amplification (Castle et al., 1993; Poulaki et al., 2001) . Given the importance of the mitochondrial pathway in N-mycaugmented apoptosis, it is not surprising that Bcl-2 inhibits the proapoptotic function of N-myc in N-myc overexpressing neuroblastoma cell lines in vitro and increases their tumorigenicity in vivo (Jasty et al., 2001) . In contrast to its well-described protective effect on mitochondrial integrity through sequestration of activated BH3 domain containing death proteins, much less is known about the ability of Bcl-2 to modulate glucose metabolism, a property, which may similarly contribute to its antiapoptotic effects (Papas et al., 1999; Kim and Kim, 2003) . c-Myc stimulates energetically inefficient glycolysis, at least partially by inducing lactate dehydrogenase A (LDH-A) (Shim et al., 1997) , a c-myc responsive gene. Such c-myc transformed glycolytic cells are prone to glucose deprivation-mediated apoptosis (Shim et al., 1998) . This may play an important role in tumors, whose microenvironment is characterized by a lack of glucose and marked acidosis, caused by limited tumor vascularization and, to some degree, the enforced glycolytic phenotype of cancer cells (Warburg effect; reviewed in (Vaupel, 2004) ). It is unknown, whether N-myc induces a glycolytic phenotype and a susceptibility to glucose deprivation-mediated apoptosis analogous to c-myc. It is also not known, whether N-myc-mediated cell death-similar to c-myc-mediated death-is attenuated wholly or in part by Bcl-2 through induction of energetically more efficient oxidative phosphorylation, and if so, whether this plays a role in neuroblastomas overexpressing N-myc.
Survivin (BIRC5) is a member of the IAP family with a dual function of inhibiting apoptosis and regulating mitosis (reviewed in (Altieri, 2003) ). Not found in adult tissue except in activated T cells (Song et al., 2005) , survivin is expressed in many tumor cells. In addition to being essential for mitosis, survivin has been implicated in G 1 to S transition (Dohi et al., 2004) . BIRC5 maps to 17q25, a region frequently gained in advanced stage neuroblastoma, and expression of survivin is associated with unfavorable features of neuroblastoma and poor outcome (Adida et al., 1998; Islam et al., 2000; Miller et al., 2006) . It is unknown, whether survivin modulates the action of N-myc in neuroblastoma.
Given that antiapoptotic mechanisms must be operative in neuroblastoma to attenuate the proapoptotic function of N-myc during trophic stress so that it can maintain its oncogenic function, we investigated systematically within the same SH-EP neuroblastoma cell line, whether overexpression of FLIP L or Bcl-2, or knockdown of survivin modulate N-myc-mediated cell death during deprivational stress. We chose SH-EP cells, one of the most widely studied neuroblastoma cell lines, for assessing the function of N-myc. SH-EP cells do not express endogenous N-myc, which facilitates the assessment of their response to forced expression of N-myc. We show, that N-myc overrides Bcl-2-mediated metabolic protection by reestablishing the glycolytic phenotype and attenuates the antiapoptotic effect of Bcl-2 during metabolic stress. Survivin afforded general protection against serum deprivation-induced cell death and, to a lesser degree, against N-myc-augmented cell death during serum deprivation. Finally, FLIP L did not counteract N-myc-augmented cell death under serum deprivation.
Results

N-mycER in SH-EP cells is activated by 4-hydroxytamoxifen
Human N-myc cDNA fused to the a-domain of the estrogen receptor was introduced into SH-EP cells to allow conditional activation of N-myc by 4-hydroxytamoxifen (4-OHT). We first investigated, whether activated N-mycER translocates into the nucleus. SH-EP cells with forced expression of N-mycER harbored N-mycER in both the cytoplasmic and nuclear compartments ( Figure 1a ). Despite apparent 'leakiness' (nuclear localization), the construct remains functionally inactive in the absence of 4-OHT. Significant activation requires the addition of 4-OHT that markedly increased the amount of N-mycER in the nuclear fraction. To determine inducible transcriptional activity of N-mycER, the expression of N-myc, myc and the bona fide N-myc target ornithine decarboxylase 1 (ODC1) was determined by real-time quantitative RT-PCR. Parental SH-EP cells, which express ODC1 and myc but not N-myc, neither transactivated ODC1 nor repressed MYC (Figure 1b) . In contrast, SH-EP cells with N-mycER responded to 4-OHT with a twofold induction of ODC1 over baseline. Expression of N-myc mRNA was detected, as expected, and myc was concomitantly repressed, in line with the welldescribed negative feedback loop of N-myc on myc (Breit and Schwab, 1989) . Thus, 4-OHT induces functional activation of N-mycER in SH-EP cells.
Activation of N-myc in SH-EP cells during serum deprivation causes caspase-dependent apoptotic cell death Since N-myc can elicit both proliferation and death of cells, we first determined the response of trophically 
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A Ushmorov et al stressed SH-EP neuroblastoma cells to activation of N-mycER. Figure 2a shows the expression of N-mycER in transduced SH-EP cells. Cells were subjected to significant trophic stress by depriving them of serum. 4-OHT exerted no or just minor unspecific cytotoxicity in mock-transfected serum-deprived SH-EP cells not expressing N-mycER ( Figure 2b ). In contrast, activation of N-mycER triggered by addition of 4-OHT caused death of SH-EP cells (Figure 2c ), leading to complete absence of viable cells by day 5. These data show that cell death, not cell proliferation, predominates, when N-myc is activated under the conditions of trophic stress. N-myc-augmented cell death was predominantly apoptotic and was dependent on caspases, since it was largely inhibited by the broad-spectrum caspase inhibitor zVAD-fmk (Figure 2d ).
Bcl-2 overexpression prevents death of SH-EP cells mediated by activation of N-myc in low-serum conditions
We wanted to confirm that Bcl-2 overexpressing SH-EP neuroblastoma cells are protected against cell death induced by N-myc. We therefore transfected parental SH-EP cells and SH-EP cells expressing N-mycER with Bcl-2 ( Figure 3a ). Bcl-2 protected nonactivated N-mycER cells from cell death caused by serum deprivation. Importantly, Bcl-2 significantly attenuated N-myc-augmented cell death during serum deprivation (Figure 3b ).
Bcl-2-mediated metabolic protection is counteracted by activated N-myc in SH-EP cells Next we asked, whether Bcl-2 exerts metabolic protection to counteract N-myc-augmented cell death in neuroblastoma cells triggered by nutritional deprivation (in distinction to serum deprivation). To simulate the microenvironment of tumors characterized by glucose deprivation and lactate acidosis, we cultivated SH-EP cells at high density in the presence of 10% serum for up to 5 days without changing medium. Indeed, under these culture conditions acidosis became evident by yellow discoloration of the medium, lactate levels increased and glucose levels dramatically decreased (Figure 4 ), the latter most likely constituting the major metabolic stressor in this system. As shown in Figure 4a , the number of viable SH-EP cells not overexpressing Bcl-2 decreased massively after 3 days. In contrast, SH-EP cells overexpressing Bcl-2 reached much higher cell densities, showing a protective effect of Bcl-2 against nutritional deprivation-induced apoptosis or growth arrest. Surprisingly, protection by Bcl-2 against metabolic stress was decreased when N-myc was activated, as the number of viable cells did not increase but decreased at later time points during metabolic stress (Figure 4a ). To investigate this unexpected phenomenon, we determined the effects of N-myc and Bcl-2 on glucose and lactate levels in the culture medium. Glucose levels rapidly declined ( Figure 4b ) and lactate levels correspondingly increased (Figure 4c ) in cells not overexpressing Bcl-2, independent of whether N-myc was activated or not. In contrast, Bcl-2 overexpression decreased glucose consumption and lactate production (Figures 4b and c, respectively), suggesting that Bcl-2 shifts cellular energy production from aerobic glycolysis (that is, the Warburg effect) to energetically more efficient oxidative phosphorylation. Activation of Nmyc in Bcl-2 overexpressing cells, however, blocked oxidative phosphorylation, as evident by increased glucose consumption and lactate production (Figures 4b and c, respectively) . This suggests that N-myc activation overrides the metabolic protection provided by Bcl-2 by reestablishing the glycolytic phenotype and that N-myc in part attenuates the antiapoptotic function of Bcl-2 during metabolic stress.
Survivin partially protects SH-EP cells from cell death and growth inhibition induced by serum deprivation and by N-myc activation during serum deprivation Since expression of survivin has been implicated in poor prognosis neuroblastoma, we investigated, whether (Figure 6a ). Interestingly, FLIP L overexpression mildly increased death of nonactivated N-mycER cells during serum deprivation (Figure 6b ). Importantly, FLIP L clearly did not inhibit N-myc-mediated cell death during serum deprivation, but rather increased cell death somewhat (Figure 6b ). Forced expression of FLIP L did not activate caspase-8, as neither p43/41 cleavage products nor the p18 active fragment were generated (Figure 6c , first lane). Prolonged serum deprivation in conjunction with forced expression of FLIP L was associated with cleavage of caspase-3 (third lane). Cleavage was enhanced by concomitant activation of N-myc (fourth lane). Taken together these data show that, in SH-EP cells, high-level FLIP L does not cooperate with N-myc in an oncogenic fashion and suggest that N-myc-induced cell death proceeds along the intrinsic pathway.
SH-EP cells surviving constitutive overexpression of N-myc grow faster in low-serum conditions
Constitutive overexpression of N-myc has been reported to increase expansion of neuroblastoma cells in lowserum conditions. Since this seemingly contrasts with our findings of suppressed neuroblastoma cell growth when N-myc is acutely activated under serum deprivation, we investigated the effect of constitutively expressed N-myc in SH-EP cells. Immediately after transfection increased levels of N-myc were detected in detached cells as compared to cells still adherent (Figure 7a ). During selection N-myc overexpression had a suppressive effect on SH-EP cells, as fewer and smaller pIRESneo2N-myc colonies arose as compared to pIRESneo2 cells (Figure 7b ). Following selection, while the difference in the percentage of viable cells during serum deprivation was negligible (Figure 7d ), pIRESneo2 N-myc cells grew faster than mock-transfected cells (Figure 7e , Po0.01 for each time point). We investigated possible mechanisms of the growth difference between SH-EP cells with activated N-mycER and with constitutive N-myc overexpression. There was no difference in the expression of the apoptosis inhibitors FLIP L , survivin, XIAP, cIAP-2 or Id2, no decreased expression of caspase-8 and no difference in N-myc-mediated upregulation of p53 (Figure 7f ).
Discussion
Despite its well-documented role in aggressive neuroblastoma, the function of N-myc in this tumor remains enigmatic. While N-myc clearly has oncogenic potential, its proapoptotic effect also classifies N-myc as a potential tumor suppressor, particularly, when its activity is deregulated and cells become incapable of downregulating N-myc function coincident with cellular stressors. The latter mechanism has been viewed as an intrinsic safeguard against N-myc's oncogenic potential. We and others hypothesize that antiapoptotic mechanisms must be operative in neuroblastoma to counteract N-myc's proapoptotic function, assuming cell intrinsic and extrinsic stressors are encountered in situ. We N-myc-augmented cell death during trophic stress A Ushmorov et al therefore set out to investigate the roles of metabolic protection by Bcl-2, survivin and FLIP L in neuroblastoma. To this end, we chose and validated the inducible N-mycER system.
In line with earlier studies, we show that acute activation of N-mycER by 4-OHT decreases the number of viable neuroblastoma cells predominantly by caspasedependent apoptosis.
Bcl-2 or alternative pro-survival homologues constitute ubiquitous and powerful antagonists of N-mycaugmented apoptosis in neuroblastoma. Herein, we confirmed that overexpression of Bcl-2 affords potent induction between SH-EP cells with constitutive overexpression of N-myc or with activated N-mycER. Cells were seeded in medium with 10% FCS. Medium was switched the following day to low serum. Twenty-four hours later, hydroxytamoxifen (4-OHT) was added where indicated. Cells were lysed 24 h later and protein expression was determined by western blot. Protein molecular weights are shown. The experiment was repeated once with similar results.
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A Ushmorov et al protection against N-myc-induced apoptosis in the setting of serum deprivation. We further investigated the hitherto undefined role of Bcl-2-mediated metabolic protection against the proapoptotic effects of N-myc. We show that in neuroblastoma cells Bcl-2 can activate oxidative phosphorylation and thus prevent apoptosis, most likely by enforcing energetically more efficient glucose consumption. However, when N-myc is activated, it enforces the glycolytic phenotype that overrides this Bcl-2-mediated protection. This property of N-myc to antagonize the function of Bcl-2 requires further investigation, since activation of N-myc in SH-EP cells induces almost no genes involved in glycolysis (Boon et al., 2001 ) and because-in our neuroblastoma model-we could not observe stimulation of glycolysis by N-myc, when Bcl-2 was not overexpressed. This is in contrast to myc overexpression in fibroblasts, where a shift to aerobic glycolysis occurs via induction of LDH-A, a target gene of myc (Shim et al., 1998; Papas et al., 1999) . This difference may be explained by the fact that neuroblastoma cells operate a priori fully by aerobic glycolysis (the Warburg effect), which cannot be enhanced further by members of the myc family such as N-myc. Of note, although in our model tumor cells benefited from activation of oxidative phosphorylation, most likely due to energetically more efficient glucose consumption, glycolysis may be essential for tumor progression as shown by LDH-A knockdown (Fantin et al., 2006) . Although LDH-A deficient cells increased oxidative phosphorylation, their ability to proliferate under hypoxia and to form tumors was severely diminished. This suggests that simultaneous expression of Bcl-2 and N-myc should empower neuroblastoma cells by combining the antiapoptotic effect of Bcl-2 with the hypoxia resistance provided by the proglycolytic activity of N-myc and with the tumorigenic properties of N-myc. Of note, we did not study the potential for Bcl-2 homologues such as Bcl-X L or myeloid cell leukemia-1 to afford similar protection against N-myc-mediated apoptosis during trophic stress. In neuroblastoma tumors it remains possible that overexpression of such alternative members of this pro-survival family may afford similar protection should they have affinity for those as yet undefined BH3 proteins activated under such circumstances.
We have investigated the hitherto undefined role of survivin in modulating the effect of N-myc in neuroblastomas during trophic stress. We show that survivin protects SH-EP neuroblastoma cells against the trophic stress of serum deprivation. This general protection by survivin extends in part to N-myc-augmented cell death during serum deprivation, although it was less pronounced than the protection afforded by Bcl-2. This may be explained by the fact that survivin, unlike other IAP proteins, which strongly inhibit apoptosis, has only a single IAP domain (Ambrosini et al., 1997) and may thus be less potent in repressing effector caspases downstream of mitochondrial death signals. Our data lend some support to the reported role of survivin expression as a predictor of poor outcome. Furthermore, they suggest that therapeutic repression of survivin, for example, by small interfering RNA approaches, may be efficacious in N-myc overexpressing neuroblastomas, such as neuroblastomas with amplified MYCN.
The function of FLIP L is controversial and variable. We investigated, whether FLIP L attenuates N-mycaugmented growth suppression in neuroblastoma cells. FLIP L expressed at high levels did not afford protection against N-myc-mediated death of SH-EP cells during serum deprivation. In fact, high-level FLIP L mildly enhanced N-myc-induced cell death, associated with enhanced cleavage of caspase-3, the mechanisms of which have yet to be elucidated. These data argue against high-level FLIP L as an oncogenic antagonist of the proapoptotic function of N-myc in neuroblastoma cells. However, we have not investigated the effect of FLIP L at intermediate levels, which may be more typical of the situation in tumors and which may have a protective effect against N-myc-induced apoptosis.
The emerging evidence that N-myc may induce death of neuroblastoma cells unless cell death antagonists are operative appears to contrast with previous publications, where stable overexpression of N-myc increased growth of serum-deprived neuroblastoma cells (Schweigerer et al., 1990; Jasty et al., 2001) . However, closer examination of the mechanism of stable transfection of N-myc reconciles these seemingly contradictory results. We show that N-myc has also a suppressive effect during transfection and selection for constitutive expression of N-myc. In contrast, constitutive overexpression of N-myc in cells surviving the period of selection has a growth promoting effect. We assume that cell death preventing mechanisms must have developed during selection allowing the growth promoting effects of N-myc to dominate. Changes in the expression of FLIP L , XIAP, cIAP-2, survivin or Id2, decreased expression of caspase-8 or differences in N-mycmediated upregulation of p53 are not among these mechanisms, as we have shown. Future studies comparing global expression profiles of SH-EP N-mycER cells with activated N-mycER and SH-EP pIRESneo2-N-myc cells may delineate additional molecules antagonizing the tumor suppressive effects of N-myc.
The extent of transactivation by N-myc may be different for constitutive overexpression of pIRESneo2N-myc as compared to conditional activation of N-mycER. Such differences could play a role in whether N-myc suppresses or enhances neuroblastoma cells. This may have contributed to the differences in cell death and proliferation we observed between SH-EP cells with activated N-mycER or with overexpressed pIRESneo2N-myc.
In summary, N-myc ablates the metabolic protection and diminishes the antiapoptotic function of Bcl-2 during metabolic stress, while survivin but not FLIP L provide a degree of protection against N-myc-augmented cell death during serum deprivation stress. This sheds new light on the function of N-myc in trophically stressed SH-EP neuroblastoma cells.
Materials and methods
Cell lines and media
Human neuroblastoma SH-EP cells (Ross et al., 1983) and their derivatives were maintained under 5% CO 2 at 37 1C in RPMI 1640 medium (Life Technologies, Karlsruhe, Germany) containing 10% fetal calf serum with low levels of estrogen activity as determined by the manufacturer (Biochrom, Munich, Germany). Glutamine (2 mM), 100 U ml À1 penicillin and 100 mg ml À1 streptomycin were added. SH-EP pcDNA Bcl-2 cells (designated Bcl-2) and the corresponding mocktransfected control cell line SH-EP pcDNA (designated pcDNA) were a gift from Dr G Nunez, University of Michigan Medical School.
Vector constructs
The retroviral construct pBabe-puro-N-mycER includes a chimera between human N-myc (with a mutated final codon) in frame with the human estrogen receptor-a ligand binding domain, cloned into the EcoRI restriction site of the retroviral vector pBabe-puro (the plasmid was generously provided by Dr William Weiss, UCSF). The pIRESneo2-N-myc construct was made by cloning human N-myc from the pGem3-N-myc vector into the EcoRI restriction site of the pIRESneo2 vector (Clontech, Heidelberg, Germany) using standard techniques.
Transfection SH-EP cells were transfected with pcDNA3-cFLIP L (a kind gift from Dr P Krammer, German Cancer Research Center) using the GenePorter transfection reagent (GTS Inc., San Diego, CA, USA) and selected with 700 mg ml À1 of neomycin (Life Technologies). One of several clones strongly expressing FLIP L was selected and designated FLIP L . SH-EP cells were also transfected with the constructs pIRESneo2 and pIRESneo2-N-myc using GenePorter. Corresponding bulk cultures were selected by 800 mg ml À1 of neomycin and were designated pIRESneo2 and N-myc. For experiments, the cells were seeded in collagen-I-coated six-well plates (Becton Dickinson, Heidelberg, Germany) in culture medium without neomycin.
Retroviral transduction
The retroviral construct pBabe-puro-N-mycER was cotransfected with a pVSV-G plasmid (Clontech) into the pantropic packaging cell line GP293 (Clontech) using GenePorter. SH-EP cells, pcDNA cells, Bcl-2 cells and FLIP L cells were transduced by incubating the cells for 3 h with retroviral supernatant diluted 1:5 with culture medium in the presence of 8 mg ml À1 of hexadimethrine bromide (Sigma, Munich, Germany). Transduced cells were selected by 1.5 mg ml À1 puromycin (Clontech) yielding bulk cultures designated pBabe, N-mycER, pcDNA N-mycER, Bcl-2 N-mycER and FLIP L N-mycER cells, respectively. Established cultures were propagated in culture medium containing 1 mg ml À1 puromycin (N-mycER cells) or additional 600 mg ml À1 neomycin (Life Technology; pcDNA N-mycER, Bcl-2 N-mycER and FLIP L N-mycER cells).
Real-time quantitative RT-PCR Cells were subconfluently cultured in complete media with and without 200 or 400 nM 4-OHT over 48 h. Total RNA (2 mg) was reverse-transcribed in a 20 ml reaction using the SuperScript III First Strand Synthesis System (Invitrogen, Carlsbad, CA, USA). The probes and primer set used were Assay-onDemand Hs00159739_m1 for ODC1, Hs00232074_m1 for N-myc and Hs00153408_m1 for myc (Applied Biosystems, Foster City, CA, USA). Mean expression values from three reactions were obtained in replicate experiments using Taqman (Applied Biosystems). Target gene expression was determined by the C t method, and expression of the genes of interest was normalized to the mean for neural housekeeping genes succinate dehydrogenase complex (Hs00417200_m1) and hypoxanthine phosphoribosyl transferase (Hs99999909_m1) (Fischer et al., 2005) .
Measurement of cell number and viability
Cells were harvested by trypsin/EDTA and counted using the CASY cell counter (Scha¨rfe System GmbH, Reutlingen, Germany). The percentage of viable (propidium iodide extruding) cells was assessed by flow cytometry after staining with 1 mg ml À1 of propidium iodide in phosphate-buffered saline (PBS). The absolute number of viable cells per well was calculated by multiplying the number of cells with the percentage of propidium iodide negative cells.
Apoptosis assay and caspase inhibition
Apoptosis was assessed by fluorescence-activated cell sorter analysis (FACScalibur and CellQuest software, Becton Dickinson), determining DNA fragmentation after lysing cells in hypotonic solution (0.1% sodium citrate, 0.1% Triton X-100) containing 50 mg ml À1 propidium iodide as described (Nicoletti et al., 1991) . For inhibition of caspases the broad-spectrum inhibitor zVAD-fmk was used (Calbiochem, Bad Soden, Germany).
Clonogenicity assay
Colonies were stained with 0.75% crystal violet solution containing 50% ethanol, 1.57% formaldehyde and 0.25% NaCl in water.
N-mycER translocation
Parental SH-EP and N-mycER cells were cultured in complete media with and without 200 and 400 nM 4-OHT. Fractionated nuclear and cytosolic protein lysates were obtained as previously described (Liu et al., 2007) . Protein was electrophoresed through a 10% polyacrylamide gel (Bio-Rad, Hercules, CA, USA) and transferred to polyvinylidene difluoride membranes (Immun-Blot, Bio-Rad). N-mycER was visualized with a primary antibody to ERa (1:200; sc-8002, Santa Cruz, CA, USA), goat anti-mouse secondary antibody with chemiluminescence detection (Immun-Star AP Goat Anti-Mouse detection Kit, Bio-Rad) according to the manufacturer's instructions.
Western blot analysis
Cells were grown in 100 mm culture dishes until confluent, washed twice with PBS, lysed on ice with 2 Â concentrated sample buffer (70 mM TRIS, 11.15% v/v glycerol, 0.0015% bromphenol blue, 3% SDS and 5% v/v 2-mercaptoethanol; pH 6.8), sonicated and heated for 5 min at 99 1C. Lysates (20 ml) were separated on a 10-20% gradient SDS polyacrylamide gel electroblotted onto Hybond enhanced chemiluminescence substrate (ECL) nitrocellulose membrane (Amersham, Braunschweig, Germany). Membranes were blocked for 1 h in PBS supplemented with 5% milk powder and 0.1% Tween 20. N-myc protein was detected by mouse monoclonal antibody B8.4.B (1:500; BD Pharmingen), N-mycER fusion protein by mouse monoclonal antibody E-0646 against a-estrogen receptor (1:1000; Sigma), caspase-8 by mouse monoclonal antibody clone 12F5 (Alexis, San Diego, CA, USA; 1:2000), caspase-3 by rabbit anti-human polyclonal antibody no. 9662 (Cell Signaling, Danvers, MA, USA; 1:1000), Bcl-2 by mouse monoclonal antibody sc-509
